Tag: Press Releases
-
Biodesix Announces impactful Clinical Data on the Primary Immune Response (PIR) test at the IASLC 2022 Therapies of Lung Cancer Meeting
BOULDER, Colo.— (BUSINESS WIRE)—March 3, 2022— Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced impactful data on the Primary Immune Response (PIR) test at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting. In this body of work, the PIR test provided two classifications of…
-
Biodesix Adds Dr. Charles Watts to Board of Directors
-
Biodesix Adds Dr. Robert Georgantas III to Executive Leadership Team
-
Biodesix Adds Dr. Charles Watts to Board of Directors
-
Biodesix, Immodulon Collaborating on Pancreatic Cancer Biomarkers
NEW YORK – Biodesix, Boulder, Colo, said today that it is collaborating with immune-oncology firm Immodulon Therapeutics to identify proteomic markers linked to pancreatic cancer.
-
Biodesix Reaches Agreement to Deliver Next-Generation Sequencing Assay for Blood-Based Companion Diagnostic Solutions in Cancer
-
Biodesix to Acquire Oncimmune in the United States
-
Biodesix Previews Data for Osimertinib Resistance and Precision of Liquid Biopsy at AACR
-
Biodesix VeriStrat Data Demonstrate Independent Prediction of Immunotherapy Outcomes for NSCLC Patients
-
MRM Proteomics and Biodesix Partner to Develop Precision Lung Cancer Diagnostics